EHA
16 sierpnia 2021
Virtual 26th Annual European Hematology Association (EHA) Congress, June 9-17, 2021
Rok
2021
Cel
RVU120 (CDK8/CDK19), daposertib (MEN1703 / SEL24), PIM/FLT3
Zasoby na tej stronie
Pobierz zasoby
- plik pdf
"RVU120/SEL120 CDK8/19 inhibitor - a drug candidate for the treatment of MDS can induce erythroid differentiation in transformed CD34+ hematopoietic progenitor cells"
Pobierz - plik pdf
"CLI120-001 Phase 1b Study of SEL120/RVU120 in patients with AML or High Risk MDS: Preliminary clinical and PK results from initial dose escalation cohorts"
Pobierz - plik pdf
“Results from DIAMOND-01 (CLI24-001) TRIAL: First in Human Study of SEL24/MEN1703, a Dual PIM/FLT3 Kinase Inhibitor, in Patients with Acute Myeloid Leukemia”
Pobierz